Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema.
controlled
EVIDENCE COMPARISON
DirectionalDelgocitinib
vs Dupilumab
for Barrier Integrity
Early or indirect evidence suggests delgocitinib may provide 20% better barrier integrity for skin moisture compared to dupilumab.
1.20x
Effect ratio
Delgocitinib
Favored
1
Study
Direct
Comparison
ExploratorySubjective endpointMoisture
Limits: Includes subjective endpoint · Early-stage evidence tier
How to read this claim
Kept public as exploratory because it includes subjective endpoint; early-stage evidence tier.
Some study-specific context may affect how broadly this comparison generalizes.